Skip to main content
SpringerLink
Log in

Treatment of asymptomatic hyperuricemia complicated by renal damage: a controversial issue

  • Nephrology - Review
  • Published:
International Urology and Nephrology Aims and scope Submit manuscript

Abstract

The prevalence of asymptomatic HUA is increasing year after year. HUA is a risk factor for the occurrence and development of renal diseases. However, the role of urate-lowering therapy in asymptomatic HUA complicated by renal damage is still controversial. In some experiments, the treatment of asymptomatic HUA complicated by renal damage may delay the progression of kidney damage. In addition, there is increasing evidence, suggesting that elevated serum uric acid is an independent risk factor for kidney disease. However, in other studies, uric acid-lowering therapy did not improve renal function, and uric acid levels could not be used as an independent predictor for CKD development. Further experimental studies are needed to determine the starting threshold and target value of asymptomatic HUA complicated by renal damage. At the same time, confirmation of the benefits of urate-lowering therapy for kidneys requires studies with larger samples and high-quality RCTs.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Saag KG, Choi H (2006) Epidemiology, risk factors, and lifestyle modifications for gout. Arthritis Res Ther 8(Suppl. 1):S2

    PubMed  PubMed Central  Google Scholar 

  2. Richette P, Bardin T (2010) Gout. Lancet 375(9711):318–328

    CAS  PubMed  Google Scholar 

  3. Lin KC, Lin HY, Chou P (2000) Community based epidemiological study on hyperuricemia and gout in Kin-Hu, Kinmen. J Rheumatol 27(4):1045

    CAS  PubMed  Google Scholar 

  4. Johnson RJ et al (2003) Is there a pathogenetic role for uric acid in hypertension and cardiovascular and renal disease? Hypertension 41(6):1183–1190

    CAS  PubMed  Google Scholar 

  5. Esparza Martín N, García Nieto V (2011) Hypouricemia and tubular transport of uric acid. Nefrologia 31(1):44–50. https://doi.org/10.3265/Nefrologia.pre2010.Oct.10588

    Article  PubMed  Google Scholar 

  6. Einollahi B, Einollahi H, Rostami Z (2011) Elderlyrenal transplant recipients and renal dysfunction: a risk factor for hyperuricemia. Exp Clin Transpl 9(6):376-38

    Google Scholar 

  7. Johnson RJ et al (2005) Resurrection of uric acid as a causal risk factor in essential hypertension. Hypertension 45(1):28

    Google Scholar 

  8. Satirapoj B et al (2011) High levels of uric acid correlate with decline of glomerular filtration rate in chronic kidney disease. J Med Assoc Thai 93(suppl 6):S65–S70

    Google Scholar 

  9. Ben-Dov IZ, Kark JD (2011) Serum uric acid is a GFR independent long-term predictor of acute and chronic renal insufficiency: the Jerusalem Lipid Research Clinic cohort study. Nephrol Dial Transplant 26(8):2558–2566

    CAS  PubMed  PubMed Central  Google Scholar 

  10. De Miguel E et al (2012) Diagnosis of gout in patients with asymptomatic hyperuricaemia: a pilot ultrasound study. Ann Rheum Dis 71(1):157–158

    PubMed  Google Scholar 

  11. Thiele RG, Schlesinger N (2010) Ultrasonography shows disappearance of monosodium urate crystal deposition on hyaline cartilage after sustained normouricemia is achieved. Rheumatol Int 30:495–503

    PubMed  Google Scholar 

  12. Viggiano D et al (2018) Urate-lowering agents in asymptomatic hyperuricemia: role of urine sediment analysis and musculoskeletal ultrasound. Kidney Blood Press Res 43(2):606–615

    CAS  PubMed  Google Scholar 

  13. Badve SV et al (2011) Challenges of conducting a trial of uric-acid-lowering therapy in CKD. Nat Rev Nephrol 7(5):295–300

    CAS  PubMed  Google Scholar 

  14. Lee JE et al (2006) Serum uric acid is associated with microalbuminuria in prehypertension. Hypertension 47(5):962–967

    CAS  PubMed  Google Scholar 

  15. Tseng CH (2005) Correlation of uric acid and urinary albumin excretion rate in patients with type 2 diabetes mellitus in Taiwan. Kidney Int 68(2):796–801

    CAS  PubMed  Google Scholar 

  16. Iseki K et al (2001) Significance of hyperuricemia on the early detection of renal failure in a cohort of screened subjects. Hypertens Res 24(6):691–697

    CAS  PubMed  Google Scholar 

  17. Ryoo JH et al (2013) The association between uric acid and chronic kidney disease in Korean men: a 4-year follow-up study. J Korean Med Sci 28(6):855–860

    CAS  PubMed  PubMed Central  Google Scholar 

  18. Kawashima M et al (2011) Association between asymptomatic hyperuricemia and new-onset chronic kidney disease in Japanese male workers: a long-term retrospective cohort study. BMC Nephrol 12:31

    PubMed  PubMed Central  Google Scholar 

  19. Momoki K et al (2017) Hyperuricemia as a predictive marker for progression of nephrosclerosis: clinical assessment of prognostic factors in biopsy-proven arterial/arteriolar nephrosclerosis. J Atheroscler Thromb 24(6):630–642

    CAS  PubMed  PubMed Central  Google Scholar 

  20. Wu J et al (2017) Asymptomatic hyperuricemia and coronary artery disease in elderly patients without comorbidities. Oncotarget 8(46):80688–80699

    PubMed  PubMed Central  Google Scholar 

  21. Srivastava A et al (2018) Uric acid and the risks of kidney failure and death in individuals with CKD. Am J Kidney Dis 71(3):362–370

    CAS  PubMed  Google Scholar 

  22. Nieradko-Iwanicka B (2018) What is the role of angiotensin receptor blockers in treatment of hyperuricemia coexisting with arterial hypertension? Reumatologia 56(2):106–110

    PubMed  PubMed Central  Google Scholar 

  23. Zhao Y et al (2018) Effects of sodium-glucose co-transporter 2 (SGLT2) inhibitors on serum uric acid level: a meta-analysis of randomized controlled trials. Diabetes Obes Metab 20(2):458–462

    CAS  PubMed  Google Scholar 

  24. Petreski T et al (2019) Asymptomatic hyperuricemia and cardiovascular mortality in patients with chronic kidney disease who progress to hemodialysis. Int Urol Nephrol 51(6):1013–1018

    CAS  PubMed  Google Scholar 

  25. Kim Y et al (2015) Effect of urate lowering therapy on renal disease progression in hyperuricemic patients with chronic kidney disease. J Rheumatol 42(11):2143–2148

    CAS  PubMed  Google Scholar 

  26. Siu YP et al (2006) Use of allopurinol in slowing the progression of renal disease through its ability to lower serum uric acid level. Am J Kidney Dis 47(1):51–59

    CAS  Google Scholar 

  27. Liu P et al (2015) Allopurinol treatment improves renal function in patients with type 2 diabetes and asymptomatic hyperuricemia: 3-year randomized parallel-controlled study. Clin Endocrinol (Oxf) 83:475–482

    CAS  Google Scholar 

  28. Sircar D et al (2015) Efficacy of febuxostat for slowing the GFR decline in patients with CKD and asymptomatic hyperuricemia: a 6-month, double-blind, randomized, placebo-controlled trial. Am J Kidney Dis 66:945–950

    CAS  Google Scholar 

  29. Goicoechea M et al (2015) Allopurinol and progression of CKD and cardiovascular events: long-term follow-up of a randomized clinical trial. Am J Kidney Dis 65(4):543–549

    CAS  PubMed  Google Scholar 

  30. Zeng XX et al (2018) Efficacy of febuxostat in hyperuricemic patients with mild-to-moderate chronic kidney disease: a meta-analysis of randomized clinical trials: a PRISMA-compliant article. Medicine (Baltimore) 97(13):e0161

    CAS  Google Scholar 

  31. Liu X et al (2019) The urate-lowering efficacy and safety of febuxostat versus allopurinol in Chinese patients with asymptomatic hyperuricemia and with chronic kidney disease stages 3-5. Clin Exp Nephrol 23(3):362–370

    CAS  Google Scholar 

  32. Sarvepalli PS et al (2018) Study of therapeutic efficacy of febuxostat in chronic kidney disease stage IIIA to stage VD. Saudi J Kidney Dis Transpl 29(5):1050–1056

    Google Scholar 

  33. Chini LSN, Assis LIS, Lugon JR (2017) Relationship between uric acid levels and risk of chronic kidney disease in a retrospective cohort of Brazilian workers. Braz J Med Biol Res 50(9):e6048

    CAS  PubMed  PubMed Central  Google Scholar 

  34. Kim CS et al (2017) Relationship between serum uric acid and mortality among hemodialysis patients: retrospective analysis of Korean end-stage renal disease registry data. Kidney Res Clin Pract 36(4):368–376

    PubMed  PubMed Central  Google Scholar 

  35. Kimura K et al (2018) Febuxostat therapy for patients with stage 3 CKD and asymptomatic hyperuricemia: a randomized trial. Am J Kidney Dis 72(6):798–810

    CAS  Google Scholar 

  36. Tanaka K et al (2015) Renoprotective effects of febuxostat in hyperuricemic patients with chronic kidney disease: a parallel-group, randomized, controlled trial. Clin Exp Nephrol 19:1044–1053

    CAS  PubMed  Google Scholar 

  37. Kanbay M et al (2011) A randomized study of allopurinol on endothelial function and estimated glomular filtration rate in asymptomatic hyperuricemic subjects with normal renal function. Clin J Am Soc Nephrol 6:1887–1894

    CAS  PubMed  PubMed Central  Google Scholar 

  38. Jalal D et al (2017) Vascular function and uric acid-lowering in stage 3 CKD. J Am Soc Nephrol 28(3):943–952

    CAS  PubMed  Google Scholar 

  39. Beddhu S et al (2016) A randomized controlled trial of the effects of febuxostat therapy on adipokines and markers of kidney fibrosis in asymptomatic hyperuricemic patients with diabetic nephropathy. Can J Kidney Health Dis 3:2054358116675343

    PubMed  PubMed Central  Google Scholar 

  40. Sanchez-Lozada LG et al (2005) Mild hyperuricemia induces vasoconstriction and maintains glomerular hypertension in normal and remnant kidney rats. Kidney Int 67(1):237–247

    PubMed  Google Scholar 

  41. Kang DH et al (2002) A role for uric acid in the progression of renal disease. J Am Soc Nephrol 13(12):2888–2897

    CAS  PubMed  Google Scholar 

  42. Corrado A et al (2006) Pathogenesis, clinical findings and management of acute and chronic gout. Minerva Med 97(6):495–509

    CAS  PubMed  Google Scholar 

  43. Khanna D et al (2012) 2012 American College of Rheumatology guidelines for management of gout. Part 1: systematic nonpharmacologic and pharmacologic therapeutic approaches to hyperuricemia. Arthritis Care Res 64:1431–1446

    CAS  Google Scholar 

  44. Vargas-Santos AB, Neogi T (2017) Management of gout and hyperuricemia in CKD. Am J Kidney Dis 70(3):422–439

    CAS  PubMed  PubMed Central  Google Scholar 

  45. Stamp L, Dalbeth N (2017) Urate-lowering therapy for asymptomatic hyperuricaemia: a need for caution. Semin Arthritis Rheum 46(4):457–464

    PubMed  Google Scholar 

  46. Yamanaka H (2011) Japanese Society of Gout and Nucleic Acid Metabolism. Japanese guideline for the management of hyperuricemia and gout: second edition. Nucleosides Nucleotides Nucleic Acids 30(12):1018–1029

    CAS  PubMed  Google Scholar 

  47. Hakoda M, Kasagi F (2018) Increasing trend of asymptomatic hyperuricemia under treatment with urate-lowering drugs in Japan. Mod Rheumatol 1–5

  48. Bellomo G, Selvi A (2018) Uric acid: the lower the better? Contrib Nephrol 192:69–76

    PubMed  Google Scholar 

  49. Ramirez MEG, Bargman JM (2017) Treatment of asymptomatic hyperuricemia in chronic kidney disease: a new target in an old enemy—a review. J Adv Res 8(5):551–554

    CAS  PubMed  PubMed Central  Google Scholar 

  50. Eleftheriadis T et al (2017) Asymptomatic hyperuricemia and chronic kidney disease: narrative review of a treatment controversial. J Adv Res 8(5):555–560

    CAS  PubMed  PubMed Central  Google Scholar 

  51. Bardin T, Richette P (2017) Impact of comorbidities on gout and hyperuricaemia: an update on prevalence and treatment options. BMC Med 15(1):123

    PubMed  PubMed Central  Google Scholar 

  52. Carnovale C, Venegoni M, Clementi E (2014) Allopurinol overuse in asymptomatic hyperuricemia: a teachable moment. JAMA Intern Med 174:1031–1032

    PubMed  Google Scholar 

  53. Gutierrez-Macias A et al (2005) Fatal allopurinol hypersensitivity syndrome after treatment of asymptomatic hyperuricaemia. Br Med J 331:623–624

    Google Scholar 

  54. Chamorro A et al (2016) Neuroprotection in acute stroke: targeting excitotoxicity, oxidative and nitrosative stress, and inflammation. Lancet Neurol 15:869–881

    CAS  PubMed  Google Scholar 

  55. Shen C et al (2013) Serum urate and the risk of Parkinson’s disease: results from a meta-analysis. Can J Neurol Sci 40:73–79

    PubMed  Google Scholar 

Download references

Funding

This work was supported by fundamental research funds for central universities (2042018kf0142).

Author information

Authors and Affiliations

  1. Department of Nephrology, Zhongnan Hospital of Wuhan University, 169 Donghu Road, Wuhan, 430071, Hubei, China

    Chun Hu & Xiaoyan Wu

Authors
  1. Chun Hu
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Xiaoyan Wu
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Xiaoyan Wu.

Ethics declarations

Conflict of interest

All authors declare that they have no conflict of interest.

Ethical approval

This article does not contain any studies with human participants or animals performed by any of the authors.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Hu, C., Wu, X. Treatment of asymptomatic hyperuricemia complicated by renal damage: a controversial issue. Int Urol Nephrol 51, 2227–2233 (2019). https://doi.org/10.1007/s11255-019-02256-5

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11255-019-02256-5

Keywords

Search

Navigation